Fibrosing interstitial lung diseases with a progressive phenotype involve worsening respiratory symptoms, reduced lung function, and increased fibrosis. It was a pleasure to talk with Dr. Eric Matteson (Mayo Clinic College of Medicine and Science, Rochester, MN, USA) around the pathology of progressive fibrosing interstitial lung diseases and the challenges and unmet needs in their treatment.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON.’ (Abstract number: 0186) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- Could you give us a brief overview of progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis? (0:17)
- What are the challenges and unmet needs in the treatment of these ILDs? (1:18)
Disclosures: Eric Matteson discloses consulting for Boehringer Ingelheim and Alvotech Inc; receiving honoraria from Practice Point Communications and Boehringer Ingelheim; participating on speaker’s bureaus for Practice Point Communications; and other financial support from UpToDate and Horizon Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
